AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29280723 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy without adjustment of challenge-skill balance
Number of subjects: 56
Study 27702796 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV and cytology co-testing (intervention)
Number of subjects: 43339
Study 27702796 — intervention group
Group type: COMPARATOR
Intervention: Cytology testing only (control)
Number of subjects: 43339
Study 27702796 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV negative women aged at least 40 years
Number of subjects: 43339
Study 27702796 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women with negative cytology, HPV 16/18 genotyping, and/or repeat cytology
Number of subjects: 43339
Study 25050368 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelium-on CXL
Number of subjects: 20
Study 25050368 — intervention group
Group type: COMPARATOR
Intervention: Epithelium-off CXL
Number of subjects: 20
Study 21962296 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (first day post surgery)
Number of subjects: 104
Study 21962296 — intervention group
Group type: COMPARATOR
Intervention: Control (bed rest with elevation until day 2 post surgery)
Number of subjects: 104
Study 19875994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) using TANITA TBF-300
Number of subjects: 382
Study 19875994 — intervention group
Group type: EXPERIMENTAL
Intervention: New ethnic-specific prediction equations generated from the entire sample
Number of subjects: 382
Study 19875994 — intervention group
Group type: COMPARATOR
Intervention: Deuterium (D(2)O) as the reference method
Number of subjects: 382
Study 18757050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone for 10 days
Number of subjects: 123
Study 18757050 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 123
Study 15856076 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide (up to 40 mg/day)
Number of subjects: 105
Study 15856076 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (up to 1000 mg/day)
Number of subjects: 105
Study 15856076 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 14716965 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol combination 250/50 micrograms one inhalation twice daily
Number of subjects: 246
Study 14716965 — intervention group
Group type: COMPARATOR
Intervention: CFC beclomethasone dipropionate 250 micrograms two puffs twice daily plus montelukast 10 mg in the evening
Number of subjects: 246
Study 11010699 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group educational intervention for urinary incontinence
Number of subjects: 108
Study 11010699 — intervention group
Group type: COMPARATOR
Intervention: Wait control condition
Number of subjects: 108
Study 8195464 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 225
Study 8195464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 225
Study 8195464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 3296225 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 26
Study 3296225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31923729 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 1961
Study 29679336 — intervention group
Group type: EXPERIMENTAL
Intervention: MGB-OAGB
Number of subjects: 201
Study 29679336 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 201
Study 27634081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstrings stretching alone
Number of subjects: 42
Study 27634081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstrings stretching combined with ischemic compression of the masseter muscle
Number of subjects: 42
Study 26350445 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based preventive intervention targeting moral disengagement, empathy, and social cognitive predictors of cyberbullying
Number of subjects: 355
Study 26350445 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 355
Study 22673870 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation measures (IG)
Number of subjects: 477
Study 22673870 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (WG)
Number of subjects: 477
Study 22673870 — intervention group
Group type: COMPARATOR
Intervention: Rejected group (AG)
Number of subjects: 477
Study 21292553 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational school-based intervention (4 sessions of 50 minutes each)
Number of subjects: 104
Study 21292553 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational school-based intervention
Number of subjects: 104
Study 19517673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block using Winnie technique
Number of subjects: 75
Study 19517673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block using Moore technique
Number of subjects: 75
Study 19517673 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (Winnie and Moore)
Number of subjects: 75
Study 17289172 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and paclitaxel (Group A)
Number of subjects: 40
Study 17289172 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone and docetaxel (Group B)
Number of subjects: 40
Study 17289172 — intervention group
Group type: COMPARATOR
Intervention: Control Group C (female patients with heart failure)
Number of subjects: 40
Study 17289172 — intervention group
Group type: COMPARATOR
Intervention: Control Group D (healthy women)
Number of subjects: 40
Study 15537846 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 15537846 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin or somatostatin combined with endoscopic ligation or sclerotherapy
Number of subjects: 0
Study 15537846 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockers
Number of subjects: 0
Study 15537846 — intervention group
Group type: COMPARATOR
Intervention: Band ligation
Number of subjects: 0
Study 15537846 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies targeting intrahepatic resistance
Number of subjects: 0
Study 11345477 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage condition
Number of subjects: 0
Study 11345477 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic condition
Number of subjects: 0
Study 11345477 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational cue (low inhibition in Study 1)
Number of subjects: 0
Study 11345477 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational cue (high instigation in Study 2)
Number of subjects: 0
Study 9046455 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (six sessions of high-velocity, low-amplitude manipulation to the cervical and upper thoracic regions during a 3-4 week period)
Number of subjects: 20
Study 9046455 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises (two unsupervised sessions daily over the same time period)
Number of subjects: 20
Study 7702382 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag in bottle system
Number of subjects: 20
Study 2571497 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methylparatyrosine
Number of subjects: 24
Study 2571497 — intervention group
Group type: COMPARATOR
Intervention: methysergide
Number of subjects: 24
Study 905580 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg PGE2 vaginal suppositories
Number of subjects: 48
Study 905580 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin induction (with or without estrogen pre‐treatment)
Number of subjects: 48
Study 905580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 48
Study 31881392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg orally once daily
Number of subjects: 2000
Study 31881392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 30844878 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR 300/300 mg
Number of subjects: 487
Study 30844878 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR 300/100 mg
Number of subjects: 487
Study 30844878 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR
Number of subjects: 487
Study 30844878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 28203010 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional printing custom trays using FSD system
Number of subjects: 20
Study 28203010 — intervention group
Group type: COMPARATOR
Intervention: Conventional custom trays fabricated manually
Number of subjects: 20
Study 25323784 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC)
Number of subjects: 12
Study 25323784 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 12
Study 23109222 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU cholecalciferol per week
Number of subjects: 318
Study 23109222 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU cholecalciferol per week
Number of subjects: 318
Study 23109222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 21308781 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (20 patients, 3 mg daily)
Number of subjects: 41
Study 21308781 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (21 patients, 15 mg daily)
Number of subjects: 41
Study 19363695 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (200 ml containing 12.5% maltodextrin) given 2 hours before operation
Number of subjects: 21
Study 19363695 — intervention group
Group type: COMPARATOR
Intervention: 8 hours fasting (control group)
Number of subjects: 21
Study 16222548 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg on alternate days for 1 year)
Number of subjects: 56
Study 16222548 — intervention group
Group type: COMPARATOR
Intervention: Control (low-dose prednisolone <0.5 mg/kg on alternate days for 1 year)
Number of subjects: 56
Study 12734506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene cream 0.1%
Number of subjects: 1303
Study 12734506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene cream 0.05%
Number of subjects: 1303
Study 12734506 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1303
Study 10679495 — intervention group
Group type: COMPARATOR
Intervention: Weight loss intervention
Number of subjects: 181
Study 10679495 — intervention group
Group type: COMPARATOR
Intervention: Dietary sodium reduction intervention
Number of subjects: 181
Study 9301382 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 0.8‐0.9 mg kg‐1 orally, 45 min before induction of anaesthesia
Number of subjects: 24
Study 9301382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative medication)
Number of subjects: 24
Study 8130356 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression (complete avoidance of steroids or withdrawal of steroids less than 3 months after transplantation)
Number of subjects: 7
Study 8130356 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy (control group)
Number of subjects: 7
Study 3481333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200mg once daily
Number of subjects: 30
Study 3481333 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400mg twice daily
Number of subjects: 30
Study 31935146 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser (three times weekly for 8 weeks)
Number of subjects: 26
Study 31935146 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 26
Study 29717337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Number of subjects: 54
Study 29717337 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 54
Study 29717337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise modes
Number of subjects: 54
Study 29717337 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 27783027 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 140
Study 27783027 — intervention group
Group type: COMPARATOR
Intervention: Standard care program
Number of subjects: 140
Study 25876341 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy
Number of subjects: 60
Study 25876341 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of flunarizine hydrochloride capsules (5mg, once every night for 14 days)
Number of subjects: 60
Study 25876341 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of flunarizine hydrochloride capsules
Number of subjects: 60
Study 25876341 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy and medicine group
Number of subjects: 60
Study 21563952 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction phase (no oral hygiene for 21 days)
Number of subjects: 30
Study 21563952 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution phase (home care reinstated until 35 days)
Number of subjects: 30
Study 21563952 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of salivary IL‐6 and IL‐8
Number of subjects: 30
Study 21563952 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of IL‐6 and MMP‐1 at baseline
Number of subjects: 30
Study 20463812 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (a macrolide antibiotic)
Number of subjects: 0
Study 20463812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 18677972 — intervention group
Group type: EXPERIMENTAL
Intervention: Suplatast tosilate (300 mg/day)
Number of subjects: 10
Study 15657324 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month quality improvement intervention (n = 211)
Number of subjects: 418
Study 15657324 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 207)
Number of subjects: 418
Study 12562485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with fentanyl 1 microg.kg(‐1) (group BF)
Number of subjects: 75
Study 12562485 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with midazolam 50 microg.kg(‐1) (group BM)
Number of subjects: 75
Study 12562485 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone (group B)
Number of subjects: 75
Study 10100652 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐msec pulsed ruby laser at fluences from 10 to 40 J/cm2
Number of subjects: 24
Study 8894860 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine plus 1500 IU hyaluronidase
Number of subjects: 33
Study 8894860 — intervention group
Group type: COMPARATOR
Intervention: 1% lignocaine
Number of subjects: 33
Study 2005233 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel
Number of subjects: 10
Study 2005233 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% stannous fluoride gel
Number of subjects: 10
Study 2005233 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride gel (1.25% fluoride)
Number of subjects: 10
Study 2005233 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10
Study 7046500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg
Number of subjects: 30
Study 7046500 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid 100 mg
Number of subjects: 30
Study 31382932 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-Care Pathway (SCP)
Number of subjects: 1400
Study 31382932 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1400
Study 31382932 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 1400
Study 31382932 — intervention group
Group type: COMPARATOR
Intervention: Online Cognitive Behavioral Therapy (CBT)
Number of subjects: 1400
Study 29191450 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 1.1 mL (275 mg) of hydroxyprogesterone caproate (HPC) administered using an autoinjector
Number of subjects: 90
Study 29191450 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of 1 mL (250 mg) of hydroxyprogesterone caproate (HPC)
Number of subjects: 90
Study 26611244 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncinectomy
Number of subjects: 29
Study 26611244 — intervention group
Group type: COMPARATOR
Intervention: Balloon Sinuplasty
Number of subjects: 29
Study 26611244 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (as a factor)
Number of subjects: 29
Study 26611244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene Blue Test
Number of subjects: 29
Study 24061764 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg
Number of subjects: 90
Study 24061764 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin 10 mg
Number of subjects: 90
Study 24061764 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 20814889 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assembled peptide nanospheres
Number of subjects: 0
Study 20814889 — intervention group
Group type: COMPARATOR
Intervention: Aβ(1-42) peptide
Number of subjects: 0
Study 20079177 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 65
Study 20079177 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 65
Study 17201545 — intervention group
Group type: EXPERIMENTAL
Intervention: More information about others
Number of subjects: 0
Study 17201545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguity (lack of information)
Number of subjects: 0
Study 17201545 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about others
Number of subjects: 0
Study 17201545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-date data from online daters
Number of subjects: 0
Study 15500103 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution (1,000 ml, n=8)
Number of subjects: 32
Study 15500103 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch (1,000 ml, n=9)
Number of subjects: 32
Study 15500103 — intervention group
Group type: EXPERIMENTAL
Intervention: No preload (n=10)
Number of subjects: 32
Study 15500103 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency group (n=5)
Number of subjects: 32
Study 15500103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preload)
Number of subjects: 32
Study 11474722 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who believed in catharsis and venting anger
Number of subjects: 0
Study 11474722 — intervention group
Group type: COMPARATOR
Intervention: Mood-freezing pill
Number of subjects: 0
Study 11474722 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with high anger-out tendencies
Number of subjects: 0
Study 11474722 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire data from Studies 3 and 4
Number of subjects: 0
Study 11474722 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures from Study 5
Number of subjects: 0
Study 9558806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 8
Study 9558806 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclectic treatment programs
Number of subjects: 8
Study 9558806 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive clinical treatment including hypnosis
Number of subjects: 8
Study 7894340 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (30 micrograms/d)
Number of subjects: 16
Study 7894340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3308390 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine (100 mg b.i.d.)
Number of subjects: 104
Study 3308390 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50 mg b.i.d.)
Number of subjects: 104
Study 31892277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic resistance exercise with an elastic resistance band
Number of subjects: 70
Study 31892277 — intervention group
Group type: COMPARATOR
Intervention: Isometric contraction exercises
Number of subjects: 70
Study 28986271 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (Echo) and cardiac magnetic resonance imaging (cMRI) assessments
Number of subjects: 48
Study 28986271 — intervention group
Group type: EXPERIMENTAL
Intervention: cMRI
Number of subjects: 48
Study 28986271 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (Echo)
Number of subjects: 48
Study 27530656 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 824
Study 27530656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study 25004024 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin in patients with pulmonary embolism
Number of subjects: 1653
Study 25004024 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in patients with pulmonary embolism
Number of subjects: 1653
Study 25004024 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin in patients without pulmonary embolism
Number of subjects: 1653
Study 25004024 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) in patients without pulmonary embolism
Number of subjects: 1653
Study 20859765 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Limited Care‐Coordination (TLC), an eight‐week co‐occurring disorders intervention
Number of subjects: 102
Study 20859765 — intervention group
Group type: COMPARATOR
Intervention: Matched Attention (MA) control condition in the form of health education sessions
Number of subjects: 102
Study 19804963 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV+O(2)
Number of subjects: 34
Study 19804963 — intervention group
Group type: COMPARATOR
Intervention: O(2) alone
Number of subjects: 34
Study 18476954 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 18
Study 18476954 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 18
Study 16120455 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-mail communications with phone follow-up
Number of subjects: 424